SEATTLE, WA--(Marketwired - May 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in booth 2019 at McCormick Place.

The ForeCYTE Breast Health Test, developed and marketed by Atossa Genetics, detects reversible precancerous conditions in the breast up to eight years before they become cancer. The test uses a hand-held, FDA Class II medical device that is quick, painless, and non-invasive and can be administered during an OB/GYN office visit. Unlike mammograms, which are commonly recommended for women starting at age 40 to 50, the ForeCYTE Breast Health Test is more age agnostic, uses no radiation and does not require invasive biopsy needles or surgical incisions. To view a video about the ForeCYTE Test, click here: https://vimeo.com/62365818.

"We believe that our ForeCYTE Breast Health Test represents a breakthrough in breast cancer risk assessment testing. The ForeCYTE test can provide vital early detection of cancer or precancerous conditions and therefore help prevent breast cancer and save lives. We look forward to presenting the ForeCYTE test's value at ASCO, the largest gathering of oncologists in the nation," said Chris Destro, Vice President of Atossa, who will attend the exhibition.

Atossa's ForeCYTE Breast Health Test is available through physicians nationwide.

About the ASCO Annual Meeting

The ASCO annual meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making an excellent venue for exploring the theme of the Meeting -- "Building Bridges to Conquer Cancer."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information on Atossa and the ForeCYTE test, please visit http://www.atossagenetics.com.

Continued here:
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the 2013 ASCO Annual Meeting

Comments are closed.